Nabumetone
Template:Short description Script error: No such module "redirect hatnote". Script error: No such module "Unsubst". Template:Cs1 config Template:Short description <templatestyles src="Infobox drug/styles.css"/> Script error: No such module "Infobox".Script error: No such module "TemplatePar".Template:Infobox drug/maintenance categories
Nabumetone, sold under the brand name Relafen among others, is a nonsteroidal anti-inflammatory drug (NSAID).[2][3] Nabumetone was developed by Beecham and first received regulatory approval in 1991.[4]
Nabumetone is a non-acidic NSAID prodrug that is rapidly metabolized in the liver to the active metabolite, 6-methoxy-2-naphthyl acetic acid. Nabumetone's active metabolite inhibits the cyclooxygenase enzyme and preferentially blocks COX-2 activity (which is indirectly responsible for the production of inflammation and pain during arthritis). The active metabolite of nabumetone is felt to be the compound primarily responsible for therapeutic effect. Comparatively, the parent drug is a poor inhibitor of COX-2 byproducts, particularly prostaglandins. It may be less nephrotoxic than indomethacin.[5] There are two known polymorphs of the compound.[6] Nabumetone has little effect on renal prostaglandin secretion and less of an association with heart failure than other traditional drugs of the class.[7] Effects of nabumetone on blood pressure control in hypertensive patients on ACE inhibitors are also good,Script error: No such module "Unsubst". equivalent to paracetamol.[8]
In 2022, it was the 239th most commonly prescribed medication in the United States, with more than 1Script error: No such module "String".million prescriptions.[9][10]
Medical uses
Nabumetone is indicated for relief of signs and symptoms of osteoarthritis and rheumatoid arthritis.[2]
Side effects
Side effects include bloody or black, tarry stools; change in color, frequency, or amount of urine; chest pain; shortness of breath; coughing up blood; pale stools; numbness; weakness; flu-like symptoms; leg pain; vision problems; speech problems; problems walking; weight gain; stomach pain; cold sweat; skin rash; blisters; headache; swelling; bleeding; bruising; vomiting blood; jaundice; diarrhea; constipation; dizziness; indigestion; gas; nausea; and ringing in the ears.[11]
In October 2020, the US Food and Drug Administration (FDA) required the prescription drug label to be updated for all nonsteroidal anti-inflammatory medications to describe the risk of kidney problems in unborn babies that result in low amniotic fluid.[12][13] They recommend avoiding NSAIDs in pregnant women at 20 weeks or later in pregnancy.[12][13]
Society and culture
Brand names
It is sold under many brand names, including Relafen,[2] Relifex, and Gambaran.
References
<templatestyles src="Reflist/styles.css" />
- ↑ Script error: No such module "Citation/CS1".
- ↑ a b c Cite error: Script error: No such module "Namespace detect".Script error: No such module "Namespace detect".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "Citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ Script error: No such module "citation/CS1".
- ↑ a b Script error: No such module "citation/CS1". Public Domain This article incorporates text from this source, which is in the public domain.
- ↑ a b Script error: No such module "citation/CS1". Public Domain This article incorporates text from this source, which is in the public domain.
Script error: No such module "Check for unknown parameters".
Script error: No such module "Navbox". Template:Prostanoid signaling modulators Template:Portal bar Script error: No such module "Authority control".